James L. Abbruzzese
James L. Abbruzzese
Professor of Medicine, Duke University
Verified email at
Cited by
Cited by
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
G Steinbach, PM Lynch, RKS Phillips, MH Wallace, E Hawk, GB Gordon, ...
New England Journal of Medicine 342 (26), 1946-1952, 2000
Pancreatic cancer
D Li, K Xie, R Wolff, JL Abbruzzese
The Lancet 363 (9414), 1049-1057, 2004
Phase II trial of curcumin in patients with advanced pancreatic cancer
N Dhillon, BB Aggarwal, RA Newman, RA Wolff, AB Kunnumakkara, ...
Clinical cancer research 14 (14), 4491-4499, 2008
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
MJ Ratain, TIM Eisen, WM Stadler, KT Flaherty, SB Kaye, GL Rosner, ...
Journal of Clinical Oncology 24 (16), 2505-2512, 2006
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer
T Arumugam, V Ramachandran, KF Fournier, H Wang, L Marquis, ...
Cancer research 69 (14), 5820-5828, 2009
Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy
GR Varadhachary, EP Tamm, JL Abbruzzese, HQ Xiong, CH Crane, ...
Annals of surgical oncology 13, 1035-1046, 2006
The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells
W Wang, JL Abbruzzese, DB Evans, L Larry, KR Cleary, PJ Chiao
Clinical Cancer Research 5 (1), 119-127, 1999
Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus
MM Hassan, LY Hwang, CJ Hatten, M Swaim, D Li, JL Abbruzzese, ...
Hepatology 36 (5), 1206-1213, 2002
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
JL Abbruzzese, R Grunewald, EA Weeks, D Gravel, T Adams, B Nowak, ...
Journal of Clinical Oncology 9 (3), 491-498, 1991
Metastatic patterns in adenocarcinoma
KR Hess, GR Varadhachary, SH Taylor, W Wei, MN Raber, R Lenzi, ...
Cancer 106 (7), 1624-1633, 2006
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head
DB Evans, GR Varadhachary, CH Crane, CC Sun, JE Lee, PWT Pisters, ...
Journal of Clinical Oncology 26 (21), 3496-3502, 2008
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up …
HW Lo, SC Hsu, W Xia, X Cao, JY Shih, Y Wei, JL Abbruzzese, ...
Cancer research 67 (19), 9066-9076, 2007
Antidiabetic therapies affect risk of pancreatic cancer
D Li, SCJ Yeung, MM Hassan, M Konopleva, JL Abbruzzese
Gastroenterology 137 (2), 482-488, 2009
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway
Z Wang, Y Li, D Kong, S Banerjee, A Ahmad, AS Azmi, S Ali, ...
Cancer research 69 (6), 2400-2407, 2009
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group–directed intergroup trial …
PA Philip, J Benedetti, CL Corless, R Wong, EM O'Reilly, PJ Flynn, ...
Journal of clinical oncology 28 (22), 3605, 2010
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis
D Wei, X Le, L Zheng, L Wang, JA Frey, AC Gao, Z Peng, S Huang, ...
Oncogene 22 (3), 319-329, 2003
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
CJ Bruns, CC Solorzano, MT Harbison, S Ozawa, R Tsan, D Fan, ...
Cancer research 60 (11), 2926-2935, 2000
Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas.
FR Spitz, JL Abbruzzese, JE Lee, PW Pisters, AM Lowy, CJ Fenoglio, ...
Journal of Clinical Oncology 15 (3), 928-937, 1997
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial
HQ Xiong, A Rosenberg, A LoBuglio, W Schmidt, RA Wolff, J Deutsch, ...
Journal of clinical oncology 22 (13), 2610-2616, 2004
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma
JR Hecht, R Bedford, JL Abbruzzese, S Lahoti, TR Reid, RM Soetikno, ...
Clinical Cancer Research 9 (2), 555-561, 2003
The system can't perform the operation now. Try again later.
Articles 1–20